GLP-1 receptor agonists like semaglutide and tirzepatide work differently: they stimulate insulin secretion, slow gastric emptying, and reduce appetite through central nervous system signaling
For upcoming obesity drugs, key areas of competition are expected to include reducing the number of annual injections, shifting to oral medications, and lowering side effects, muscle loss and rebound weight gain
Tirzepatide has the most extensive published literature, with FDA approval, multiple completed Phase 3 trial programs (SURMOUNT, SURPASS), and extensive real-world evidence
Patients with specific FTO rs9939609 variants, for example, show enhanced response to GLP-1 receptor agonists but may require different dosing strategies than those with wild-type alleles
Brak specjalnych zalece dotyczcych temperatury przechowywania leku
Frequently Asked Questions Is it safe to inject semaglutide directly into the stomach muscle